• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Selective Immunosuppressants
    6 Drugs classified under this drug class


    All the Drug Class Drugs

    Entyvio
    Takeda
    RX
    partial basket chart
    Entyvio

    Selective Immunosuppressants. Vedolizumab 300 mg.
    VIAL (pwdr. for conc. for sol. for infus.): 1. Ulcerative colitis: 300 mg admin. by IV infus. at zero, two and six wks. and then every 8 wks. thereafter. Ther. for pts. with ulcer. colit. should be discont. if no evidence of therapeutic benefit is observed by wk 10.
    Pts. who exper. decr. in response may incr. in dosing freq. to 300 mg every 4 wks.
    Pts. who have respond. to tmt. with 300 mg, corticost. may be reduced and/or discount. in accord. with standard of care. 2. Crohn’s disease: 300 mg admin. by IV infus. at zero, two and six wks. and then every 8 wks. thereafter.
    Pts. with Crohn’s dis., who have not shown a response may benefit from a dose at wk 10. Ther. should be cont. every 8 wks. from wk 14 in respond. pts. Therapy for pts. with Crohn’s dis. should be discont. if no eviden. of therap. benefit is observ. by wk 14. See lit.
    Tmt. of adult pts. with moder.-sever. act. ulcer. colitis who have had an inadeq. response with, lost response to, or were intolerant to either convent. ther. or a TNFα antagonist.
    Tmt. of adult pts. with moder.-sever. act Crohn’s dis. who have had an inadeq. response with, lost response to, or were intolerant to either convent. ther. or a ther. or a TNFα antagonist.
    C/I: Hypersens. Act. severe infec. such as tuberculosis, sepsis, CMV, listeriosis, and opportunis. infec. such as PML.

    Lemtrada
    Sanofi
    RX
    partial basket chart
    Lemtrada

    Selective Immunosuppressants. Alemtuzumab 10 mg/ml.
    VIAL (conc. for sol. for infus.): 1 x 12 mg.
    Recom. dose is 12 mg/d admin. by IV
    infus. for 2 tmt. courses. Init. tmt.
    course: 12 mg/d for 5 consec. days (60
    mg total dose). 2nd tmt. course: 12
    mg/d for 3 consec. days (36 mg total
    dose) admin. 12 mths. after the init.
    tmt. course.
    Adult pts. with RRMS with active dis.
    defined by clinical or imaging features.
    C/I: Hypersens.

    Orencia
    BMS
    RX
    partial basket chart
    Orencia

    Selective Immunosuppressants. Abatacept 125 mg/ml, 250 mg.
    PRE-FILLED SYRINGE: 4 Syr (single dose)
    125 mg SC inj. once wkly. W or w/o an
    IV load. dose. Pts. transit. from IV ther.
    to SC administ. 1st SC dose instead of
    the next scheduled IV dose.
    Reduct. signs and symp., inducing
    major clinic. response, inhib. the
    progress. of struct. damage, and
    improve. phys. func. in adult pts. with
    moderat. to severe. act. RA.
    Used as monother.or concom. DMARDs
    other than TNF antagonists.
    VIAL (pwdr for conc. for infus.): 1x250mg. See lit.
    As monotherapy for tmt. mod.-severe
    active rheum. arthrit. in adults with
    DMARDs other than TNF antagonists . A
    reduct. in progress. joint damage and
    improv. phys. funct. have been
    demonstrat. In combinat. tmt. with abatacept and methotrexate. In
    combinat.with methotrexate for tmt.
    mod.-severe active polyarticul. juvenile
    idiopathic arthrit. (JIA) in ped. pts 6 yrs of
    age and older, with insuffic. response to
    other DMARDs incl. at least one TNF
    inhibitor. Has not been studied in child. <
    6 yrs.
    C/I: Should not be administered
    concomitantly with TNF antagonists. Is
    not recommended for use
    concomitantly with other biologic
    rheumatoid arthritis (RA) therapy.

    Otezla
    Neopharm
    RX
    partial basket chart
    Otezla

    Selective Immunosuppressants. Apremilast 10, 20, 30 mg.
    F.C. TAB: Init. Pack: 4 x 10 mg, 4 x 20 mg, 19 x 30 mg; 56 x 30 mg.
    Recommend. dose 30 mg x 2 /d, every 12 h. Init. titration require. See lit.
    Tmt. of adult pts. with active psoriatic arthritis. For pts. with mod. to sev. plaque psoriasis who are candid. for photother. or syst. ther.
    C/I: Hypersens.,pregn.

    CLOSE